Avatrombopag
Doptelet (avatrombopag) is a small molecule pharmaceutical. Avatrombopag was first approved as Doptelet on 2018-05-21. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. It is known to target thrombopoietin receptor. Doptelet's patents are valid until 2025-05-05 (FDA).
Trade Name | Doptelet |
---|---|
Common Name | Avatrombopag |
Indication | thrombocytopenia |
Drug Class | Thrombopoetin agonists |